Marcus Schulz Biography and Net Worth

CRO of BioLife Solutions

Marcus Schulz started at BioLife in 2020 as Vice President of Global Sales and was promoted to Chief Revenue Officer in 2021. He brings 20 years of healthcare experience to the Biolife executive leadership team.

Prior to joining BioLife in 2019, Marcus served in a variety of strategic business development and executive sales leadership roles with such leading companies as Siemens Healthcare, Johnson & Johnson, Abbott Laboratories and most recently, GE Healthcare. Marcus consistently delivers exceptional results, driving record revenues and growing market share in highly competitive and complex market segments.

He thinks of himself as a customer advocate and takes pride in building strong, lasting relationships through an in-depth understanding of each customer’s unique needs. He excels at identifying and nurturing talent and developing and leading strong teams. Marcus holds a B.A. from Villanova University.

What is Marcus Schulz's net worth?: The estimated net worth of Marcus Schulz is at least $1.15 million as of August 25th, 2023. Mr. Schulz owns 42,097 shares of BioLife Solutions stock worth more than $1,153,037 as of December 21st. This net worth approximation does not reflect any other investments that Mr. Schulz may own. Learn More about Marcus Schulz's net worth.
How do I contact Marcus Schulz?: The corporate mailing address for Mr. Schulz and other BioLife Solutions executives is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. BioLife Solutions can also be reached via phone at (425) 402-1400 and via email at [email protected]. Learn More on Marcus Schulz's contact information.
Has Marcus Schulz been buying or selling shares of BioLife Solutions?: Marcus Schulz has not been actively trading shares of BioLife Solutions within the last three months. Most recently, Marcus Schulz sold 347 shares of the business's stock in a transaction on Friday, August 25th. The shares were sold at an average price of $10.99, for a transaction totalling $3,813.53. Following the completion of the sale, the executive now directly owns 42,097 shares of the company's stock, valued at $462,646.03. Learn More on Marcus Schulz's trading history.
Who are BioLife Solutions' active insiders?: BioLife Solutions' insider roster includes Sarah Aebersold (VP), Todd Berard (CMO), Roderick de Greef (CFO), Karen Foster (Insider), Andrew Hinson (Director), Aby Mathew (VP), Michael Rice (CEO), Joseph Schick (Director), Marcus Schulz (CRO), and Troy Wichterman (CFO). Learn More on BioLife Solutions' active insiders.
Are insiders buying or selling shares of BioLife Solutions?: In the last twelve months, insiders at the medical equipment provider sold shares 75 times. They sold a total of 143,570 shares worth more than $2,926,356.42. The most recent insider tranaction occured on December, 16th when EVP Aby J Mathew sold 7,604 shares worth more than $207,817.32. Insiders at BioLife Solutions own 2.2% of the company. Learn More about insider trades at BioLife Solutions.
Information on this page was last updated on 12/16/2024.

Marcus Schulz Insider Trading History at BioLife Solutions

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/25/2023	Sell	347	$10.99	$3,813.53	42,097
8/14/2023	Sell	108	$12.38	$1,337.04	42,444
7/24/2023	Sell	679	$19.50	$13,240.50	42,552
7/11/2023	Sell	331	$22.79	$7,543.49	43,231
5/15/2023	Sell	75	$18.71	$1,403.25	43,899
4/19/2023	Sell	430	$19.33	$8,311.90	41,062
4/14/2023	Sell	215	$21.05	$4,525.75	41,492
4/6/2023	Sell	771	$20.03	$15,443.13	41,707
3/1/2023	Sell	903	$22.75	$20,543.25	42,478
2/9/2023	Sell	56	$24.60	$1,377.60	43,381
1/23/2023	Sell	1,000	$25.02	$25,020.00	43,437
1/18/2023	Sell	3,000	$25.04	$75,120.00	44,975
1/11/2023	Sell	258	$21.94	$5,660.52	47,975
11/10/2022	Sell	40	$23.16	$926.40	35,500
10/28/2022	Sell	400	$21.76	$8,704.00	35,540
10/14/2022	Sell	236	$21.80	$5,144.80	35,940
8/10/2022	Sell	42	$23.17	$973.14	36,176
8/3/2022	Sell	4,600	$20.03	$92,138.00	36,218
7/22/2022	Sell	367	$17.94	$6,583.98	40,818
7/12/2022	Sell	254	$15.79	$4,010.66	41,185
5/13/2022	Sell	41	$12.32	$505.12	41,439
4/21/2022	Sell	477	$13.94	$6,649.38	41,480
4/18/2022	Sell	286	$17.59	$5,030.74	41,957
2/10/2022	Sell	167	$29.38	$4,906.46
1/20/2022	Sell	395	$30.24	$11,944.80
1/12/2022	Sell	267	$32.18	$8,592.06
11/9/2021	Sell	1,750	$53.00	$92,750.00
10/20/2021	Sell	399	$42.34	$16,893.66
10/11/2021	Sell	245	$38.22	$9,363.90
7/26/2021	Sell	4,919	$45.65	$224,552.35
7/20/2021	Sell	2,539	$45.10	$114,508.90	36,366
7/8/2021	Sell	240	$45.73	$10,975.20
4/20/2021	Sell	650	$32.10	$20,865.00	39,145
4/8/2021	Sell	224	$35.77	$8,012.48	39,795
1/12/2021	Sell	2,000	$41.01	$82,020.00	37,107
1/8/2021	Sell	293	$39.01	$11,429.93	39,107
11/12/2020	Sell	1,400	$32.51	$45,514.00	39,400
10/12/2020	Sell	953	$28.20	$26,874.60	41,753

Marcus Schulz Buying and Selling Activity at BioLife Solutions

BioLife Solutions Company Overview

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

Today's Range

Now: $27.39

$25.13

$28.63

50 Day Range

MA: $24.96

$20.47

$27.47

2 Week Range

Now: $27.39

$14.50

$28.88

Volume

1,077,464 shs

Average Volume

386,862 shs

Market Capitalization

$1.27 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.91

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."

I put all the details together for you here — but please hurry.